Evidence map›Paper›PMID 41357974›Full record

ArticlebioRxiv : the preprint server for biology2025

ATHENA: A deep learning-based AI for functional prediction of genomic mutations and synergistic vulnerabilities in prostate cancer.

Siyuan Cheng, Xiao Jin, Jiaying Qian, Yuyin Jiang, Isaac Yi Kim, Su Deng, Ping Mu

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Siyuan ChengDepartment of Urology, Yale University School of Medicine, New Haven, CT, 06511.
Xiao JinDepartment of Urology, Yale University School of Medicine, New Haven, CT, 06511.
Jiaying QianDepartment of Urology, Yale University School of Medicine, New Haven, CT, 06511.
Yuyin JiangDepartment of Urology, Yale University School of Medicine, New Haven, CT, 06511.
Isaac Yi KimDepartment of Urology, Yale University School of Medicine, New Haven, CT, 06511.
Su DengDepartment of Urology, Yale University School of Medicine, New Haven, CT, 06511.
Ping MuDepartment of Urology, Yale University School of Medicine, New Haven, CT, 06511.ORCID 0000-0003-0955-0896

Funding

Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI Eric P. Winer · 1985 to 2026
$85.0M
Elucidating the Molecular Role of SYNCRIP in Prostate Cancer and AR Targeted Therapy ResistanceR37CA258730 · NCI · YALE UNIVERSITY · PI Ping Mu · 2021 to 2026
$2.7M
Unveiling the Role of UBE2J1 as the E2 Ubiquitin Conjugating Enzyme in Androgen Receptor DegradationR01CA292949 · NCI · YALE UNIVERSITY · PI Ping Mu · 2024 to 2026
$2.1M
Deciphering the Impact of ZNF397-deficiency in Promoting TET2-driven Epigenetic Rewiring, Lineage Plasticity, and Therapy Resistance in Prostate CancerR01CA288820 · NCI · YALE UNIVERSITY · PI Ping Mu · 2024 to 2026
$820k
NCI NIH HHS P30 CA016359NCI NIH HHS R01 CA288820NCI NIH HHS R01 CA292949NCI NIH HHS R37 CA258730
6 · The paper itself

Abstract

Identifying functional mutations that drive therapy resistance remains a major challenge in prostate cancer. Large-scale sequencing often produces extensive lists of mutations but provides limited insight into which alterations are functionally relevant. To overcome this gap, we developed

Identifiers

PMID41357974
PMCPMC12676378

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.